All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What are the strategies to optimize outcomes in pediatric/AYA patients receiving CAR T-cells?
Bookmark this article
During the ALL Hub Steering Committee meeting, Charles Mullighan chaired a discussion on “What are the strategies to optimize outcomes in pediatric/AYA patients receiving CAR T-cells?”, featuring Elias Jabbour, Franco Locatelli, José María Ribera, and Andrea Biondi.
The key discussion topics included:
- Key factors associated with CAR T-cell therapy success or failure
- Optimal timing of CAR T-cell therapy
- Emerging CAR T-cell therapy approaches
- How to manage relapse after CAR T-cell therapy
- Issues that should be considered when optimizing CAR T-cell therapy outcomes in pediatric/adolescent and young adult patients
What are the strategies to optimize outcomes in pediatric/AYA patients receiving CAR T-cells?
More about...
Your opinion matters
2 votes - 80 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox